“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies

Yuxing Xia,Stefan Prokop,Benoit I. Giasson

DOI: https://doi.org/10.1186/s13024-021-00460-5

2021-06-05

Molecular Neurodegeneration

Abstract:Abstract Phosphorylation is one of the most prevalent post-translational modifications found in aggregated tau isolated from Alzheimer’s disease (AD) patient brains. In tauopathies like AD, increased phosphorylation or hyperphosphorylation can contribute to microtubule dysfunction and is associated with tau aggregation. In this review, we provide an overview of the structure and functions of tau protein as well as the physiologic roles of tau phosphorylation. We also extensively survey tau phosphorylation sites identified in brain tissue and cerebrospinal fluid from AD patients compared to age-matched healthy controls, which may serve as disease-specific biomarkers. Recently, new assays have been developed to measure minute amounts of specific forms of phosphorylated tau in both cerebrospinal fluid and plasma, which could potentially be useful for aiding clinical diagnosis and monitoring disease progression. Additionally, multiple therapies targeting phosphorylated tau are in various stages of clinical trials including kinase inhibitors, phosphatase activators, and tau immunotherapy. With promising early results, therapies that target phosphorylated tau could be useful at slowing tau hyperphosphorylation and aggregation in AD and other tauopathies.

neurosciences

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the latest progress in clinical biomarkers and treatment methods for tau protein phosphorylation in Alzheimer's disease (AD) and other tauopathies. Specifically, the paper explores the following aspects:

1. **Overview of tau protein structure and function**: It introduces the basic structure, function of tau protein, as well as its expression and localization in the nervous system, emphasizing its role in microtubule stabilization and neuronal axonal transport.

2. **The role of tau protein physiological phosphorylation**: It discusses the phosphorylation process of tau protein and its changes in different physiological states, such as the changes in tau protein phosphorylation levels during development, hibernation and hypothermia, and the impact of these changes on tau protein function.

3. **Evidence of tau protein phosphorylation in AD**: It describes in detail the significant increase in tau protein phosphorylation levels in the brains of AD patients. In particular, compared with healthy controls, the differences in the number and location of tau protein phosphorylation sites in the brains of AD patients are presented. The paper also discusses the role of these phosphorylation sites in disease progression, such as tau pathological features at different stages in Braak staging.

4. **The impact of tau protein hyperphosphorylation on microtubule interaction, aggregation and prion - like spread**: It analyzes how hyperphosphorylation affects the binding ability of tau protein to microtubules, leading to misfolding and aggregation of tau protein, and may spread between cells through a prion - like mechanism.

5. **Heterogeneity of tau protein in different tauopathies**: It compares the differences in tau protein pathological features between AD and other tauopathies (such as corticobasal degeneration, progressive supranuclear palsy, etc.), including different morphologies, regional distributions and cell - type specificities.

6. **Development of p - tau CSF and plasma biomarkers**: It summarizes the progress in recent years in developing new biomarkers for detecting specific phosphorylated tau protein sites in AD and other tauopathies, especially the research on p - tau biomarkers in CSF and plasma, such as detection methods for sites such as pThr181, pThr217 and pThr231 and their potential application in disease diagnosis and monitoring.

In summary, this paper aims to provide new ideas and strategies for the early diagnosis, disease monitoring and treatment of AD and other tauopathies through comprehensive analysis of the latest research progress in tau protein phosphorylation.